Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.
Brian Hill, MD, PhD, Cleveland Clinic
Articles by Brian Hill, MD, PhD, Cleveland Clinic
Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.
Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.
Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.
Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Brian T. Hill, MD, PhD, discusses the safety profiles of BTK inhibitors in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the safety profiles of BTK inhibitors in mantle cell lymphoma.














Latest Updated Articles
Dr. Hill on the Safety Profiles of BTK Inhibitors in MCLPublished: December 7th 2020 | Updated:
SADAL Trial OverviewPublished: July 17th 2020 | Updated:
CAR T-Cell Therapy Clinical TrialsPublished: July 17th 2020 | Updated:
DLBCL Risk Assessment and Genetic SignaturesPublished: July 17th 2020 | Updated:
Therapy Initiation Prior to Cytogenetic Testing ResultsPublished: July 17th 2020 | Updated:
CAR T Cell Therapy in Relapsed/Refractory DLBCLPublished: July 17th 2020 | Updated:

